Increased formation of thromboxane in vivo in humans with mastocytosis

Jason D. Morrow, John A. Oates, L. Jackson Roberts, William E. Zackert, Tanya A. Mitchell, Gerald Sylvan Lazarus, Cynthia Guzzo

Research output: Contribution to journalArticle

Abstract

Clinical manifestations of mastocytosis are mediated, at least in part, by release of the mast cell mediators histamine and prostaglandin D2. It has been previously reported that in addition to prostaglandin D2, mast cells produce other eicosanoids, including thromboxane. Nonetheless, little information exists regarding the formation of other prostanoids in vivo. The most accurate method to examine the systemic production of eicosanoids in vivo is the quantitation of urinary metabolites. We previously developed a highly accurate assay employing mass spectrometry to measure a major urinary metabolite of thromboxane, 11-dehydro-thromboxane B2, in humans. We utilized this assay to quantitate thromboxane production in 17 patients with histologically proven mastocytosis. We report that thromboxane formation was significantly increased :>2 SD above the mean) in at least one urine sample from 65% of patients studied. Of these, 91% of patients with documented systemic involvement had elevated thromboxane generation. In addition, endogenous formation of thromboxane was highly correlated with the urinary excretion of the major urinary metabolite of prostaglandin D2 (r = 0.98) and N(τ)-methylhistamine (r = 0.91), suggesting that the cellular source of increased thromboxane in vivo could be the mastocyte. Enhanced thromboxane formation in patients with this disorder is unlikely to be of platelet origin as other markers of platelet activation, platelet factor 4 and β- thromboglobulin, were not increased in three patients with marked overproduction of thromboxane. Furthermore, the recovery of 11-dehydro- thromboxane B2 excretion in two patients after the administration of aspirin occurred significantly more rapidly than the recovery of platelet thromboxane generation. These studies, therefore, report that thromboxane production is significantly increased in the majority of patients with mastocytosis that we examined and provide the basis to elucidate the role of this eicosanoid in disorders of mast cell activation.

Original languageEnglish (US)
Pages (from-to)93-97
Number of pages5
JournalJournal of Investigative Dermatology
Volume113
Issue number1
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Mastocytosis
Thromboxanes
Prostaglandin D2
Eicosanoids
Metabolites
Platelets
Mast Cells
Assays
Blood Platelets
Chemical activation
Platelet Factor 4
Recovery
Platelet Activation
Histamine
Aspirin
Prostaglandins
Mass spectrometry
Mass Spectrometry

Keywords

  • Histamine
  • Prostaglandin D
  • Thromboxane B
  • Urticaria pigmentosa

ASJC Scopus subject areas

  • Dermatology

Cite this

Morrow, J. D., Oates, J. A., Roberts, L. J., Zackert, W. E., Mitchell, T. A., Lazarus, G. S., & Guzzo, C. (1999). Increased formation of thromboxane in vivo in humans with mastocytosis. Journal of Investigative Dermatology, 113(1), 93-97. https://doi.org/10.1046/j.1523-1747.1999.00624.x

Increased formation of thromboxane in vivo in humans with mastocytosis. / Morrow, Jason D.; Oates, John A.; Roberts, L. Jackson; Zackert, William E.; Mitchell, Tanya A.; Lazarus, Gerald Sylvan; Guzzo, Cynthia.

In: Journal of Investigative Dermatology, Vol. 113, No. 1, 1999, p. 93-97.

Research output: Contribution to journalArticle

Morrow, JD, Oates, JA, Roberts, LJ, Zackert, WE, Mitchell, TA, Lazarus, GS & Guzzo, C 1999, 'Increased formation of thromboxane in vivo in humans with mastocytosis', Journal of Investigative Dermatology, vol. 113, no. 1, pp. 93-97. https://doi.org/10.1046/j.1523-1747.1999.00624.x
Morrow, Jason D. ; Oates, John A. ; Roberts, L. Jackson ; Zackert, William E. ; Mitchell, Tanya A. ; Lazarus, Gerald Sylvan ; Guzzo, Cynthia. / Increased formation of thromboxane in vivo in humans with mastocytosis. In: Journal of Investigative Dermatology. 1999 ; Vol. 113, No. 1. pp. 93-97.
@article{e3a75b1502254d5d872ebf05adcf0abf,
title = "Increased formation of thromboxane in vivo in humans with mastocytosis",
abstract = "Clinical manifestations of mastocytosis are mediated, at least in part, by release of the mast cell mediators histamine and prostaglandin D2. It has been previously reported that in addition to prostaglandin D2, mast cells produce other eicosanoids, including thromboxane. Nonetheless, little information exists regarding the formation of other prostanoids in vivo. The most accurate method to examine the systemic production of eicosanoids in vivo is the quantitation of urinary metabolites. We previously developed a highly accurate assay employing mass spectrometry to measure a major urinary metabolite of thromboxane, 11-dehydro-thromboxane B2, in humans. We utilized this assay to quantitate thromboxane production in 17 patients with histologically proven mastocytosis. We report that thromboxane formation was significantly increased :>2 SD above the mean) in at least one urine sample from 65{\%} of patients studied. Of these, 91{\%} of patients with documented systemic involvement had elevated thromboxane generation. In addition, endogenous formation of thromboxane was highly correlated with the urinary excretion of the major urinary metabolite of prostaglandin D2 (r = 0.98) and N(τ)-methylhistamine (r = 0.91), suggesting that the cellular source of increased thromboxane in vivo could be the mastocyte. Enhanced thromboxane formation in patients with this disorder is unlikely to be of platelet origin as other markers of platelet activation, platelet factor 4 and β- thromboglobulin, were not increased in three patients with marked overproduction of thromboxane. Furthermore, the recovery of 11-dehydro- thromboxane B2 excretion in two patients after the administration of aspirin occurred significantly more rapidly than the recovery of platelet thromboxane generation. These studies, therefore, report that thromboxane production is significantly increased in the majority of patients with mastocytosis that we examined and provide the basis to elucidate the role of this eicosanoid in disorders of mast cell activation.",
keywords = "Histamine, Prostaglandin D, Thromboxane B, Urticaria pigmentosa",
author = "Morrow, {Jason D.} and Oates, {John A.} and Roberts, {L. Jackson} and Zackert, {William E.} and Mitchell, {Tanya A.} and Lazarus, {Gerald Sylvan} and Cynthia Guzzo",
year = "1999",
doi = "10.1046/j.1523-1747.1999.00624.x",
language = "English (US)",
volume = "113",
pages = "93--97",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Increased formation of thromboxane in vivo in humans with mastocytosis

AU - Morrow, Jason D.

AU - Oates, John A.

AU - Roberts, L. Jackson

AU - Zackert, William E.

AU - Mitchell, Tanya A.

AU - Lazarus, Gerald Sylvan

AU - Guzzo, Cynthia

PY - 1999

Y1 - 1999

N2 - Clinical manifestations of mastocytosis are mediated, at least in part, by release of the mast cell mediators histamine and prostaglandin D2. It has been previously reported that in addition to prostaglandin D2, mast cells produce other eicosanoids, including thromboxane. Nonetheless, little information exists regarding the formation of other prostanoids in vivo. The most accurate method to examine the systemic production of eicosanoids in vivo is the quantitation of urinary metabolites. We previously developed a highly accurate assay employing mass spectrometry to measure a major urinary metabolite of thromboxane, 11-dehydro-thromboxane B2, in humans. We utilized this assay to quantitate thromboxane production in 17 patients with histologically proven mastocytosis. We report that thromboxane formation was significantly increased :>2 SD above the mean) in at least one urine sample from 65% of patients studied. Of these, 91% of patients with documented systemic involvement had elevated thromboxane generation. In addition, endogenous formation of thromboxane was highly correlated with the urinary excretion of the major urinary metabolite of prostaglandin D2 (r = 0.98) and N(τ)-methylhistamine (r = 0.91), suggesting that the cellular source of increased thromboxane in vivo could be the mastocyte. Enhanced thromboxane formation in patients with this disorder is unlikely to be of platelet origin as other markers of platelet activation, platelet factor 4 and β- thromboglobulin, were not increased in three patients with marked overproduction of thromboxane. Furthermore, the recovery of 11-dehydro- thromboxane B2 excretion in two patients after the administration of aspirin occurred significantly more rapidly than the recovery of platelet thromboxane generation. These studies, therefore, report that thromboxane production is significantly increased in the majority of patients with mastocytosis that we examined and provide the basis to elucidate the role of this eicosanoid in disorders of mast cell activation.

AB - Clinical manifestations of mastocytosis are mediated, at least in part, by release of the mast cell mediators histamine and prostaglandin D2. It has been previously reported that in addition to prostaglandin D2, mast cells produce other eicosanoids, including thromboxane. Nonetheless, little information exists regarding the formation of other prostanoids in vivo. The most accurate method to examine the systemic production of eicosanoids in vivo is the quantitation of urinary metabolites. We previously developed a highly accurate assay employing mass spectrometry to measure a major urinary metabolite of thromboxane, 11-dehydro-thromboxane B2, in humans. We utilized this assay to quantitate thromboxane production in 17 patients with histologically proven mastocytosis. We report that thromboxane formation was significantly increased :>2 SD above the mean) in at least one urine sample from 65% of patients studied. Of these, 91% of patients with documented systemic involvement had elevated thromboxane generation. In addition, endogenous formation of thromboxane was highly correlated with the urinary excretion of the major urinary metabolite of prostaglandin D2 (r = 0.98) and N(τ)-methylhistamine (r = 0.91), suggesting that the cellular source of increased thromboxane in vivo could be the mastocyte. Enhanced thromboxane formation in patients with this disorder is unlikely to be of platelet origin as other markers of platelet activation, platelet factor 4 and β- thromboglobulin, were not increased in three patients with marked overproduction of thromboxane. Furthermore, the recovery of 11-dehydro- thromboxane B2 excretion in two patients after the administration of aspirin occurred significantly more rapidly than the recovery of platelet thromboxane generation. These studies, therefore, report that thromboxane production is significantly increased in the majority of patients with mastocytosis that we examined and provide the basis to elucidate the role of this eicosanoid in disorders of mast cell activation.

KW - Histamine

KW - Prostaglandin D

KW - Thromboxane B

KW - Urticaria pigmentosa

UR - http://www.scopus.com/inward/record.url?scp=0032775286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032775286&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1747.1999.00624.x

DO - 10.1046/j.1523-1747.1999.00624.x

M3 - Article

VL - 113

SP - 93

EP - 97

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 1

ER -